Chronic Lymphocytic Leukemia New Protocol: Zanubrutinib with Venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2025-06-02
Follicular Lymphoma New Reference: RiTUXimab alone for Follicular Lymphoma Ulas D. Bayraktar, MD 2025-05-05
Mantle cell lymphoma New Reference: Acalabrutinib with R-Bendamustine in Untreated Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-05-04
Diffuse Large B Cell Lymphoma New Protocol: Brentuximab-Rituximab-Lenalidomide for Large Cell Lymphoma Ulas D. Bayraktar, MD 2025-04-07
Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for Treatment-Naive CLL Ulas D. Bayraktar, MD 2025-03-14
Mantle cell lymphoma New Indication: Ibrutinib with Venetoclax for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-03-02
Chronic Lymphocytic Leukemia New Protocol: Acalabrutinib + Venetoclax for Fixed Duration with/without Obinutuzumab Ulas D. Bayraktar, MD 2025-02-07
Mantle cell lymphoma New Protocol: Acalabrutinib with R-Bendamustine for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-01-19
Diffuse Large B Cell Lymphoma New Drug: Glofitamab for Large B Cell Lymphoma Ulas D. Bayraktar, MD 2023-09-23
